← All indications
Obstetric Labor, Premature
Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE).
Subtype terms (1)
More specific conditions that are subtypes of Obstetric Labor, Premature in the MeSH hierarchy.
- Premature Birth
107 drugs (73 approved, 34 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (16)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (16)
- Centre Hospitalier Universitaire Vaudois
- University of Pennsylvania
- Cairo University
- Chulalongkorn University
- Mansoura University
- University of Lausanne
- University of Tehran
- Woman's Hospital, Louisiana
- Assiut University
- University of Calgary
- Emek Medical Center
- Technion University
- University of Texas at Houston
- University of Sao Paulo
- University of Barcelona
- Pennington Biomedical Research Center
Organization Involved with Phase 3 Indications (46)
- PPD
- GlaxoSmithKline
- Ain Shams University
- Hospital Italiano de Buenos Aires
- Hospital Provincial Magdalena V. de Martínez
- Hospital Universitari Son Dureta
- Luzerner Kantonsspital
- McMaster University
- MemorialCare Health System
- Pontifical Catholic University of Argentina
- Saint Thomas Hospital, Panama
- Sanpasitthiprasong Hospital
- University of Toronto
- University of Bern
- University of Zurich
- Kantonsspital Graubünden
- Mednax Center for Research, Education and Quality
- Tel Aviv University
- University of Buenos Aires
- University of California, Irvine
- University of Basel
- University of Santiago
- American University of Beirut
- Hebrew University
- Complexo Hospitalario Arquitecto Marcide
- Complexo Hospitalario de Pontevedra
- Complexo Hospitalario de Ourense
- Cantonal Hospital of St. Gallen
- University of Coruna
- Ben Gurion University
- +16 more
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (23)
- Juniper Pharmaceuticals, Inc.
- University of Arizona
- Case Western Reserve University
- Johns Hopkins University
- Seoul National University
- Stanford University
- The Baruch Padeh Medical Center, Poriya
- University of Rochester
- University of Zagreb
- University of California, Davis
- University of California, Los Angeles
- University of California, San Diego
- University of California, San Francisco
- University of Cincinnati
- University of Ljubljana
- University of Mississippi
- Sveti Duh Hospital
- Washington University in St. Louis
- Thrasher Research Fund
- Slovenian Research Agency
- Government of Croatia
- Aswan University
- Imperial College London